FDA Approval of IND Application for NAP (BioSpace)

NeoTX Therapeutics got the go-ahead from the FDA for its IND application for naptumomab estafenatox (NAP). NAP is the company’s lead Tumor Targeted Superantigen (TTS) molecule, which binds a genetically engineered bacterial determinant to the tumor surface while at the same time activating and expanding tumor specific immune cells. Credit: BioSpace.com

The release as fetched from its publisher. neotx.com ↗